Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases. (Radiointer)

January 9, 2017 updated by: Centre Leon Berard

The purpose of this study is to evaluate cost-utility analysis in order to provide recommendations to French decision-makers between vertebroplasty and radiation therapy in Bone spine metastases. Indeed, radiation therapy is often advocated a systematic way. The object of this study would be to expand the use of vertebroplasty.

Moreover, this study assess to the strategy impact on the pain control reduction and functional preservation. In fact, analgesic effect is achieved differently depending on the procedure used.Eligible patients will be recruited and registered consecutively. Patients will be randomly,

This is a health-economic multicenter, prospective, randomized with stratification according to number of vertebrae to treat (1-3 vertebrae vs 4-6 vertebrae) and center :

  • Arm A: Percutaneous vertebroplasty
  • Arm B: External radiotherapy

This is an open-label study. The expected total study period is 2.5 years (enrolment: 2 years, patient follow-up: 6 months). A total number of 304 patients with spine metastases will be recruited (152 patients/arm).

Study Overview

Detailed Description

Bone is the most common site for metastasis. In breast and prostate cancers, 70% of patients dying of their cancer have evidence of metastatic bone disease [Coleman, 2006]. Depending on their localization, bone metastases can have debilitating consequences resulting in considerable morbidity and complex demands on health care resources. Bone spine metastases are the most frequent site observed in patients with cancer of the lung, prostate, breast and hemopoetic organs. The occurrence of spinal metastases in patients with advanced cancer can cause significant morbidity, with pain and/or neurological deficit adversely affecting the patients' quality of life.

Interventional radiology takes a large place in the treatment of bone metastases. Currently, vertebroplasty appears as the most satisfactory technique for stabilization of spine metastases offering a significant improvement of the quality of life. The analgesic effect is achieved very rapidly, i.e. usually within 24 hours post-procedure. Based on several publications, around 90% of patients reported rapid pain relief following vertebroplasty with 60 to 70% of complete pain relief [Mendel, 2009].

Radiotherapy also plays a very important role in the palliative treatment of the metastatic bone. Radiotherapy is effective and well tolerated. A reduction of the pain is noticed for 70 to 80 % of the patients and begins one or two weeks after the treatment. In all, the radiotherapy increases the quality of life of the patients and can reduce the intake of analgesics [Lutz, 2011].

In a lot of cases, vertebroplasty or radiotherapy can both be performed for a same painful patient (the National Institute for Health and Clinical Excellence (NICE) approved the use of vertebroplasty for patients with spinal metastases in November 2008). Radiotherapy remains the gold-standard treatment. However, vertebroplasty could be less costly and more effective compare to radiotherapy. In fact, the superiority of vertebroplasty has been demonstrated at least in the acute post-therapeutic period with (i) more rapid autonomy recovery, (ii) reduction of antalgic intakes, and potentially less side-effects.

Study Type

Interventional

Enrollment (Actual)

7

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France
        • Institut Bergonié
      • Lyon, France
        • Centre léon bérard
      • Lyon, France
        • HCL- Hopital Edouard Herriot
      • Nice, France
        • Centre Antoine Lacassagne
      • Paris, France
        • Institut Curie
      • Strasbourg, France
        • Centre Paul Strauss
      • Villejuif, France
        • Institut Gustave Roussy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years at the day of consenting to the study
  • Patient with at least a painful spine metastasis confirmed by MRI / CT scan,
  • Localized pain at the lesion ≥ 4 (VAS),
  • Bone axial metastasis localised on ≤ 6 different vertebrae,
  • Histologically established diagnosis of cancer (lung, kidney, breast, prostate, melanoma, soft tissue sarcomas) other than hematologic malignancy, myeloma, brain tumor, germ cell tumor and bone sarcomas
  • ECOG performance status 0 to 2 (Appendix 2)
  • Minimum life expectancy of 6 months (Tokuhashi score > 8 )
  • Ability to understand and willingness for follow-up visits.
  • Covered by a medical insurance
  • Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment

Exclusion Criteria:

  • Solitary metastasis
  • SBRT indication
  • Contra-indication to vertebroplasty
  • Previous radiotherapy for pain management in the same area.
  • Patient unable to lie prone
  • Neurological deficit due to spinal cord compression,
  • Active infection,
  • Bleeding risk (platelets < 50000 and PTT > 1.5*ULN),
  • Risk of vertebral collapse (SINS score ≥ 13),
  • Impossible follow-up for social, geographical, familial or psychological reasons,
  • Patient deprived of freedom,
  • Patient enrolled in another experimental surgical trial, with therapeutic endpoint,
  • Pregnant or breastfeeding women,Pregnant or breastfeeding women (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm A
Percutaneous vertebroplasty
Other Names:
  • Vertebroplasty
Experimental: Arm B
External radiotherapy
The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1*8 Gy; 5*4 Gy and 10*3 Gy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health economics evaluation
Time Frame: 6 months after the end ot treatment

To perform a cost-utility analysis in order to provide recommendations to French decision-makers on the treatment of patients with painful spine metastases.

Incremental cost-effectiveness ratio expressed in cost per quality adjusted life year (QALY) gained

6 months after the end ot treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Budget impact analysis of vertebroplasty
Time Frame: 6 months after the end of treatment
Cost-assessment, Quality of life (EQ-5D) Quality adjusted life year,
6 months after the end of treatment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of pain reduction
Time Frame: 3 weeks, 3 months and 6 months after the end of treatment
Visual analogue scale: VAS
3 weeks, 3 months and 6 months after the end of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bertrand BR RICHIOUD, MD, Center Leon Berard

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Anticipated)

April 1, 2018

Study Completion (Anticipated)

April 1, 2018

Study Registration Dates

First Submitted

June 24, 2014

First Submitted That Met QC Criteria

June 24, 2014

First Posted (Estimate)

June 25, 2014

Study Record Updates

Last Update Posted (Estimate)

January 10, 2017

Last Update Submitted That Met QC Criteria

January 9, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spine Metastases

Clinical Trials on Percutaneous vertebroplasty

Subscribe